Comprehensive pan-cancer analysis reveals EPHB2 is a novel predictive biomarker for prognosis and immunotherapy responseShengshan Xu, Zhuming Lu, Youbin Zheng et al.|BMC Cancer|2024Cited by 50
Comparison of pembrolizumab plus chemotherapy versus concurrent or sequential radiochemotherapy in patients with driver mutation-lacking lung adenocarcinoma presenting with recurrent laryngeal nerve invasion leading to hoarseness.Zhuming Lu, Zhihui Wang, Ronggang Li et al.|Journal of Clinical Oncology|2024Cited by 10